Tests TAK-279 in adults with moderately to severely active Crohn's disease
Tests the oral drug TAK-279 against placebo in adults with active Crohn's disease.
Key facts
- Who runs it
- Takeda
- Where
- Belfast, Cambridge, and London, United KingdomSee the 5 sitesAlso in 24 other countries, 201 sites
- Trial code
- NCT06233461
- EU 2023-506704-14-00
- JRCT2051240050
- Registry title
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 268 people, planned
- Started
- 5 Mar 2024
- Expected to end
- 23 Jul 2027
- Type of study
- Interventional, 4 groups
- Treatments tested
- TAK-279
- Placebo
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderately to severely active Crohn's disease who have already tried at least one other treatment without enough benefit or could not tolerate it.
- Age
- 18 to 75 years (19 or older in South Korea)
- Sex
- All sexes can join
- Disease stage
- Moderately to severely active Crohn's disease, diagnosed at least 30 days ago, confirmed with the SES-CD and CDAI scores
- Earlier treatment
- Must have had an inadequate response, lost response, or could not tolerate at least one conventional, biologic, or advanced therapy for Crohn's disease. People who failed 3 or more classes of advanced therapies cannot join.
Main reasons for not taking part
- Other types of colitis (indeterminate, microscopic, ischemic, infectious, radiation, diverticular-related) or ulcerative colitis
- Crohn's complications that might need surgery during the study
- A current ostomy
- Failed 3 or more classes of advanced therapies
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Male or female aged 18-75 years old with diagnosis of CD for at least 30 days. In South Korea, the age requirement for adult participants is >=19 years of age
- Confirmed diagnosis of moderately to severely active CD assessed by SES-CD and CDAI
- Participants must have had an inadequate response to, loss of response to, or intolerance to at least one or more conventional, biologic, or advanced therapy for CD
Who cannot take part
- Have complications of CD that might require surgery during the study
- Participants who have failed 3 or more classes of advanced therapies
- Participants with indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease associated with colitis, and/or ulcerative colitis
- Participants with a current ostomy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United Kingdom
Also in 24 other countries, 201 sites
- South Eastern Health and Social Care Trust - The Ulster HospitalBelfast, United KingdomContact: Paul Agnew (principal investigator)Taking people
- Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation TrustCambridge, United KingdomContact: Sreedhar Subramanian (principal investigator)Taking people
- NIHR UCLH Clinical Research Facility - University College London Hospitals NHS Foundation TrustLondon, United KingdomContact: Paul Harrow (principal investigator)Taking people
- St Thomas' Hospital - Guy's & St Thomas' NHS Foundation TrustLondon, United KingdomContact: Mark Samaan (principal investigator)Taking people
- Wingate Institute for Neurogastroenterology, Wingate Clinical Trials Facility, Barts Health NHS TrustLondon, United KingdomContact: Gareth Parkes (principal investigator)Taking people
About the trial
What the trial wants to find out
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation.
Read full original descriptionShow less
The participants will be treated with TAK-279 for 52 weeks (1 year).
During the study, participants will visit their study clinic 15 times.
The 4 groups in the trial
- TAK-279 Dose 1Treatment being tested
Participants will be randomized to receive TAK-279 Dose 1 capsules with TAK-279 placebo-matching capsule orally.
Treatment: TAK-279 and Placebo
- TAK-279 Dose 2Treatment being tested
Participants will be randomized to receive TAK-279 Dose 2 capsules with TAK-279 placebo-matching capsule orally.
Treatment: TAK-279 and Placebo
- TAK-279 Dose 3Treatment being tested
Participants will be randomized to receive TAK-279 Dose 3 capsules orally.
Treatment: TAK-279
- PlaceboTreatment being tested
Participants will be randomized to receive TAK-279 placebo-matching capsules orally.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Crohn's Disease
- Plain-language title
- Tests TAK-279 in adults with moderately to severely active Crohn's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06233461, who can take part
- Record updated
- 2 November 2026